Compare Adaptive Biotechnologies Corp (ADPT) vs Monolithic Power Systems Inc (MPWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Monolithic Power Systems Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.1 (market cap $4.04B), while Monolithic Power Systems Inc trades at $1,443.26 (market cap $68.90B). The key difference: Monolithic Power Systems Inc is far larger — about 17.1× Adaptive Biotechnologies Corp's market cap, and Monolithic Power Systems Inc pays a 0.57% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | MPWR | |
|---|---|---|
Market Cap | $4.04B | $68.90B |
Sector | Health | Utilities |
52-Week High | $25.45 | $1.69K |
52-Week Low | $12.30 | $820.74 |
Enterprise Value | $4.10B | $67.51B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →
